This review critically presents the evidence of the neuroprotective effects of PPARγ in preclinical PD models and patients, and proposes potential anti-α-synucleinopathy effects of PPARγ agonists that may become suitable disease-modifying drugs. The gene discussed is PPARG; the disease is synucleinopathy.